SecBot SecBot

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NYSE· Pharmaceutical Preparations· Inc. L3· CIK 0000818686 Biotech & Drug Discovery
$42.57 −1.93 (−4.34%)
Nov 16 4:00 PM ET · prev $44.50
Market cap
$50.9B
Large cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$49.50
+16% · range $42.12–57.00
1 year
+73.1%
from $24.59 · Nov 17
30 days
+3.1%
from $41.31
52-week range
$24.21–44.50
−4% from high · low Nov 21
Avg volume 20D
7.23M
shares / day
Short interest
27.74M
≈2.4% of shares · −1.2%
Days to cover
5.3
at average volume
Insider net
−$40.0M
0 buyers · 14 sellers · since May 28
New fund stakes
4
Q2 2026 13F · 1 exit
Filing reports
45
analyzed by SecBot
SecBot read MIXED 36 reports · 90 days
Balance 3 bearish · 7 bullish · 26 neutral oldest → newest, height = score
Avg score ·High conf. 26/36

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    14 insiders sold $40.0M.

  • InstitutionsBULLISH

    Q2 2026: 48 added (4 new), 25 trimmed or exited. Largest new: Meitav Investment House $336.9M, Adage Capital Partners Gp, L.L.C $80.0M.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Median target $49.50 (+16%).

  • Short sellersSTEADY

    Short interest −1.2% to 27.74M shares. 5.3 days to cover, ≈2.4% of shares.

  • TrendUPTREND

    6% above its 50-day average. New closing high $44.50 on Nov 13.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 4.

Who's buying

13F· Q2 2026
4
new positions
1
exit
$454.7M
in new stakes
FundMoveSharesValue
Capital World InvestorsADD12,536,035$424.7M
MEITAV INVESTMENT HOUSE LTDNEW9,947,045$336.9M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCDOUBLED6,593,221$223.4M
GOLDMAN SACHS GROUP INCADD6,129,240$207.7M
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCDOUBLED3,832,465$129.8M
MILLENNIUM MANAGEMENT LLCADD3,265,321$110.6M
Assenagon Asset Management S.A.DOUBLED3,056,017$103.5M
CITIGROUP INCDOUBLED2,527,031$85.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy3Buy3Hold1Sell0Strong Sell0
12-month targets · 14 analysts

Price is inside the target range. Median implies +16%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Nov 4, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 4, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 2, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Oct 15, 2026Barclays
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$40.0M
sold · 14 insiders
DateInsiderTypeValue
Nov 12, 2026
Sabag Mark
See "Remarks"
Nov 12, 2026
SELL$2.0M
Nov 12, 2026
Sabag Mark
See "Remarks"
Nov 12, 2026
EXERCISE$1.6M
Nov 11, 2026
Daniell Richard
EVP, Europe Commercial
Nov 11, 2026
SELL$856.2K
Nov 11, 2026
Daniell Richard
EVP, Europe Commercial
Nov 11, 2026
EXERCISE$694.1K
Nov 10, 2026
BRAILER DAVID J
Director
Nov 10, 2026
AWARD3,326 sh
Nov 10, 2026
Bergwerk Dov
Interim Chief Legal Officer
Nov 10, 2026
AWARD9,433 sh
Nov 10, 2026
Francis Richard D
President and CEO
Nov 10, 2026
SELL$10.6M
Nov 9, 2026
Weiss Amir
Chief Accounting Officer
Nov 9, 2026
EXERCISE$269.1K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
27,739,194
shares short
-1.2%
vs prior settlement
5.3
days to cover
≈2.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
David J. Brailer filed a Form 3 initial statement of beneficial ownership upon becoming a non-executive director of…
3 · Impact 2/10
Nov 12, 2026 SEC
Mark Sabag, EVP of International Markets Commercial at Teva, filed a Form 144 notice of intent to sell 44,710 ordinary…
144 · Impact 2/10
Nov 12, 2026 Insider
Sabag Mark sold 44,710 shares
See "Remarks" @ $44.14 ($2.0M)
Nov 12, 2026 Insider
Sabag Mark acquired via exercise 44,710 shares
See "Remarks" @ $34.90 ($1.6M)
Nov 11, 2026 Other
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative me
Nov 11, 2026 Insider
Daniell Richard sold 20,003 shares
EVP, Europe Commercial @ $42.80 ($856.2K)
Nov 3, 2026 Press
Teva announced a license and commercialization agreement with Samsung Bioepis for two FDA-approved immunology…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Recent

SecBot reports

45 filings · 16 press releases · 7 bullish · 3 bearish · 3 mixed · 32 neutral
All TEVA filing & press-release reports (61)